A phase IV, open-label three-arm study investigating the impact of a combination of tenofovir disoproxil fumarate/emtricitabine with raltegravir or dolutegravir or elvitegravir/cobicistat on renal function in HIV-1 antiretroviral naïve patients

A phase IV, open-label three-arm study investigating the impact of a combination of tenofovir disoproxil fumarate/emtricitabine with raltegravir or dolutegravir or elvitegravir/cobicistat on renal function in HIV-1 antiretroviral naïve patients

Objectives: Tenofovir DF (TDF) remains one of the preferred backbone agents for naïve HIV patients starting antiretroviral treatment (ART). The impact of TDF on renal function and metabolic parameters may vary by anchor agent. We investigated the impact of TDF in combination with 3 different integra...

Full description

Bibliographic Details
Main Authors: Margherita Bracchi, Nicole Pagani, Alessia Dalla Pria, Ana Milinkovic, Nneka Nwokolo, Lervina Thomas, Sundhyia Mandalia, Marta Boffito, Graeme Moyle
Format: Article
Language:English
Published: Taylor & Francis Group 2021-11-01
Series:HIV Research & Clinical Practice
Subjects:
hiv
tenofovir df
raltegravir
dolutegravir
elvitegravir/cobicistat
renal function
tubular function
Online Access:http://dx.doi.org/10.1080/25787489.2021.1975610

Internet

http://dx.doi.org/10.1080/25787489.2021.1975610

Similar Items